REG - Oncimmune Hldngs PLC - Lung Test More Cost Effective Compared to CT

Oncimmune HoldingsAnnouncement

28/01/2020 07:01

RNS Number : 0735B
Oncimmune Holdings PLC
28 January 2020
 


Oncimmune Holdings plc
("Oncimmune" or the "Company")
 
EarlyCDT Lung Test More Cost Effective Compared to CT Surveillance
 
Blood Test to Speed Lung Cancer Diagnosis deemed Highly Cost Effective, NIHR Study Finds
 
28 January 2020 - Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group, is pleased to note that a recent study led by Leeds University Academic Unit of Health Economics, supported by NIHR Leeds In Vitro Diagnostics Co-operative (NIHR Leeds MIC), and funded by The National Institute for Health Research's (NIHR) SBRI programme, shows that using Oncimmune's blood test in the cancer risk assessment of indeterminate pulmonary nodules (IPNs) is highly cost effective and could accelerate the time to diagnosis. The original press release from NIHR Leeds MIC can be accessed here: https://www.leedsth.nhs.uk/research/news-blogs-and-events/latest-news/2020/01/27/blood-test-to-speed-lung-cancer-diagnosis-is-highly-cost-effective-study-finds
 
In the study, Oncimmune's EarlyCDT® Lung test was found to be more effective compared to computed tomography (CT) surveillance with an incremental cost-effectiveness ratio (ICER) of less than £2,500.
 
Lung cancer is one of the most prevalent forms of cancer and kills more women than breast and ovarian cancers combined. Five-year survival rates for breast and bowel cancer patients are 86% and 59% respectively. Both of these cancers have screening programmes. Five-year survival for lung cancer, which has no screening programme, is currently less than 10%.
 
Oncimmune's EarlyCDT Lung test is a simple ELISA blood test that measures seven lung cancer-specific antibodies and can be used for the assessment of malignancy risk in patients with IPNs.
 
Robust and easy to use, the EarlyCDT Lung test can be run in any laboratory with standard laboratory equipment and, to date, over 158,000 tests have been performed for patients worldwide. A 'kit' form of the test was CE marked in May 2017 for distribution to laboratories outside the USA.
 
Dr Adam M Hill, CEO of Oncimmune said: "We are very pleased with the results of this study demonstrating the effectiveness of EarlyCDT Lung. Leeds University Academic Unit of Health Economics and NIHR Leeds MIC were excellent delivery partners for this project. Their support in bringing the multidisciplinary teams together from across the University and the local NHS Trust, enabled us to generate further data in support of our adoption discussions with the NHS across the UK."
 
Dr Helen Radford, Director of Operations, NIHR Leeds MIC said: "This exciting and important project also included an NHS laboratory validation alongside focus groups with members of the public to understand the patient's perception in early lung cancer screening and how this blood test could help. We look forward to working with Oncimmune in the future."
 
 
-Ends-
 
 
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.com
 
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
 
finnCap (Joint Broker)
Geoff Nash, Matthew Radley, Tim Redfern
+44 (0)20 7220 0500
 
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson
+44 (0)20 7332 2500
 
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
oncimmune@fticonsulting.com
+44 (0)20 3727 1000
 
 
About Oncimmune
Beating cancer, one test at a time
 
The battle against cancer hinges on early detection and then the delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.
 
Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 158,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS trial of 12,209 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.
 
Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.
 
 
What is EarlyCDT Lung?
 
A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.
 
For more information, visit www.oncimmune.com




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RESVDLFLBFLEBBQ